PubRank

Gary Hudes

Author PubWeight™ 42.09‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006 8.16
2 Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol 2012 3.98
3 Cutaneous metastases from genitourinary malignancies. Urology 2004 2.97
4 Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009 2.69
5 Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009 2.05
6 Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009 1.99
7 New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res 2005 1.70
8 Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res 2012 1.67
9 Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 2008 1.61
10 Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res 2005 1.59
11 Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 2003 1.59
12 Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007 1.53
13 Boosting bioavailability of topotecan: what do we gain? J Clin Oncol 2002 1.39
14 Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 2009 1.21
15 Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 2011 1.15
16 Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011 1.07
17 Early stopping designs based on progression-free survival at an early time point in the initial cohort. Stat Med 2007 1.02
18 Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 2007 1.01
19 Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics 2010 0.94
20 Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009 0.94
21 Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents. J Clin Oncol 2008 0.88
22 The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. Urol Clin North Am 2003 0.81
23 Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Invest New Drugs 2013 0.78
24 A wealth of new options: a case presentation of the management of castration-recurrent prostate cancer. Semin Oncol 2012 0.75